Dr Alan Joslyn becomes president and CEO of Oragenics

He will also serve on the company’s board
of directors

Florida-based Oragenics has appointed Dr Alan Joslyn as its new president, chief executive officer and member of the board of directors.

Dr Joslyn was a founding partner of Lazarus Pharmaceuticals, and has served as chief executive officer at both Edusa Pharmaceuticals and Sentinella Pharmaceuticals.

Prior to this, he worked at Penwest Pharmaceuticals as the senior vice president of research and development, and has held senior drug development positions within Johnson & Johnson.

Dr Frederick Telling, chairman of Oragenics, said: “As Oragenics opens this new chapter, the board and I are confident that Dr Joslyn is the right person to lead the company forward.

“He has proven ability to create strategic clarity, drive innovation and ensure disciplined execution as well as a depth of experience from serving a large pharmaceutical company and smaller research oriented companies, with particular experience in gastrointestinal disease and lantibiotics.

“We believe that his passion for technology will help ensure that Oragenics continues to strive to deliver innovations that have a positive impact on people's lives.”